Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Vojtesek

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
Histopathology|November 1, 1993
Enzyme-linked immunosorbent assay for p53 in gastrointestinal malignancy: comparison with immunohistochemistryB V Joypaul, B Vojtesek, E L Newman, et al.
Oncogene|January 19, 1995
Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the proteinB Vojtesek, H Dolezalova, L Lauerova, et al.
Oncogene|September 5, 2012
Emerging roles for the pro-oncogenic anterior gradient-2 in cancer developmentE Chevet, D Fessart, F Delom, et al.
Oncogene|December 11, 1997
Tumor suppressor protein p53 binds preferentially to supercoiled DNAE Palecek, D Vlk, V Stanková, et al.
Oncogene|September 20, 2006
Expression of p53 and p53/47 are controlled by alternative mechanisms of messenger RNA translation initiationM M Candeias, D J Powell, E Roubalova, et al.
Differentiation; Research in Biological Diversity|August 1, 1993
Subtypes of non-transformed human mammary epithelial cells cultured in vitro: histo-blood group antigen H type 2 defines basal cell-derived cellsU Karsten, G Papsdorf, A Pauly, et al.
Cell Death and Differentiation|April 23, 2016
p53 isoforms regulate astrocyte-mediated neuroprotection and neurodegenerationC Turnquist, I Horikawa, E Foran, et al.
Cellular and Molecular Life Sciences : CMLS|July 9, 2005
Antiproliferative activity of olomoucine II, a novel 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitorV Krystof, I W McNae, M D Walkinshaw, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Immunochemical analysis of the p53 oncoprotein in matched primary and metastatic human tumoursJ Bartkova, J Bartek, B Vojtesek, et al.
Molecular Pathology : MP|July 31, 2002
Synthetic inhibitors of CDKs induce different responses in androgen sensitive and androgen insensitive prostatic cancer cell linesJ Mad'arová, M Lukesová, A Hlobilková, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
Histopathology|November 1, 1993
Enzyme-linked immunosorbent assay for p53 in gastrointestinal malignancy: comparison with immunohistochemistryB V Joypaul, B Vojtesek, E L Newman, et al.
Oncogene|January 19, 1995
Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the proteinB Vojtesek, H Dolezalova, L Lauerova, et al.
Oncogene|September 5, 2012
Emerging roles for the pro-oncogenic anterior gradient-2 in cancer developmentE Chevet, D Fessart, F Delom, et al.
Oncogene|December 11, 1997
Tumor suppressor protein p53 binds preferentially to supercoiled DNAE Palecek, D Vlk, V Stanková, et al.
Oncogene|September 20, 2006
Expression of p53 and p53/47 are controlled by alternative mechanisms of messenger RNA translation initiationM M Candeias, D J Powell, E Roubalova, et al.
Differentiation; Research in Biological Diversity|August 1, 1993
Subtypes of non-transformed human mammary epithelial cells cultured in vitro: histo-blood group antigen H type 2 defines basal cell-derived cellsU Karsten, G Papsdorf, A Pauly, et al.
Cell Death and Differentiation|April 23, 2016
p53 isoforms regulate astrocyte-mediated neuroprotection and neurodegenerationC Turnquist, I Horikawa, E Foran, et al.
Cellular and Molecular Life Sciences : CMLS|July 9, 2005
Antiproliferative activity of olomoucine II, a novel 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitorV Krystof, I W McNae, M D Walkinshaw, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Immunochemical analysis of the p53 oncoprotein in matched primary and metastatic human tumoursJ Bartkova, J Bartek, B Vojtesek, et al.
Molecular Pathology : MP|July 31, 2002
Synthetic inhibitors of CDKs induce different responses in androgen sensitive and androgen insensitive prostatic cancer cell linesJ Mad'arová, M Lukesová, A Hlobilková, et al.
Pageof 5